FEI WANG: Open Payments
NPI 1700535796 · IRVINE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,785 in 23 payments from 10 companies in 2025. Trend: 2023 $1,042 · 2024 $2,744 · 2025 $2,785
Food & beverage: $2,785
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 6 | $733 |
| AstraZeneca Pharmaceuticals LP | 5 | $606 |
| Novo Nordisk Inc | 4 | $485 |
| Dexcom, Inc. | 2 | $172 |
| Abbott Laboratories | 1 | $159 |
| Phathom Pharmaceuticals, Inc. | 1 | $143 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $125 |
| CeQur Corporation | 1 | $112 |
Products named: REPATHA, Ozempic, AIRSUPRA, BREZTRI, OTEZLA, Wegovy, Dexcom G6 Transmitter, FREESTYLE LIBRE 3.
Industry payments across CA — which companies pay providers there.
